Your browser doesn't support javascript.
loading
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.
Cuapio, Angelica; Boulouis, Caroline; Filipovic, Iva; Wullimann, David; Kammann, Tobias; Parrot, Tiphaine; Chen, Puran; Akber, Mira; Gao, Yu; Hammer, Quirin; Strunz, Benedikt; Pérez Potti, André; Rivera Ballesteros, Olga; Lange, Joshua; Muvva, Jagadeeswara Rao; Bergman, Peter; Blennow, Ola; Hansson, Lotta; Mielke, Stephan; Nowak, Piotr; Söderdahl, Gunnar; Österborg, Anders; Smith, C I Edvard; Bogdanovic, Gordana; Muschiol, Sandra; Hellgren, Fredrika; Loré, Karin; Sobkowiak, Michal J; Gabarrini, Giorgio; Healy, Katie; Sällberg Chen, Margaret; Alici, Evren; Björkström, Niklas K; Buggert, Marcus; Ljungman, Per; Sandberg, Johan K; Aleman, Soo; Ljunggren, Hans-Gustaf.
Afiliação
  • Cuapio A; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Boulouis C; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Filipovic I; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Wullimann D; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Kammann T; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Parrot T; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Chen P; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Akber M; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Gao Y; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Hammer Q; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Strunz B; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Pérez Potti A; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Rivera Ballesteros O; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Lange J; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Muvva JR; Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
  • Bergman P; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Blennow O; Department of Laboratory Medicine, Clinical Microbiology, Karolinska Institutet, Stockholm, Sweden.
  • Hansson L; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Mielke S; Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Nowak P; Department of Transplantation, Karolinska University Hospital, Stockholm, Sweden.
  • Söderdahl G; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Österborg A; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Smith CIE; Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Bogdanovic G; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Muschiol S; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Hellgren F; Department of Medicine Huddinge, Infectious Diseases, Karolinska Institutet, Stockholm, Sweden.
  • Loré K; Laboratory for Molecular Infection Medicine Sweden MIMS, Umeå University, Umeå, Sweden.
  • Sobkowiak MJ; Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Gabarrini G; Department of Transplantation, Karolinska University Hospital, Stockholm, Sweden.
  • Healy K; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Sällberg Chen M; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Alici E; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Björkström NK; Department of Laboratory Medicine, Translational Research Center Karolinska (TRACK), Karolinska Institutet, Stockholm, Sweden.
  • Buggert M; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
  • Ljungman P; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
  • Sandberg JK; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Aleman S; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Ljunggren HG; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Mol Med ; 28(1): 20, 2022 02 08.
Article em En | MEDLINE | ID: mdl-35135470
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Hospedeiro Imunocomprometido / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Vacina BNT162 Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Med Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Hospedeiro Imunocomprometido / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Vacina BNT162 Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Med Ano de publicação: 2022 Tipo de documento: Article